Assenagon Asset Management S.A. Increases Stock Position in Insulet Co. (NASDAQ:PODD)

Assenagon Asset Management S.A. increased its holdings in Insulet Co. (NASDAQ:PODD) by 8.4% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 104,392 shares of the medical instruments supplier’s stock after buying an additional 8,102 shares during the period. Assenagon Asset Management S.A. owned 0.15% of Insulet worth $27,254,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of PODD. Integrated Wealth Concepts LLC boosted its holdings in shares of Insulet by 1.7% in the third quarter. Integrated Wealth Concepts LLC now owns 2,561 shares of the medical instruments supplier’s stock worth $596,000 after acquiring an additional 42 shares during the period. Glenmede Trust Co. NA lifted its holdings in Insulet by 2.3% during the 3rd quarter. Glenmede Trust Co. NA now owns 2,080 shares of the medical instruments supplier’s stock worth $484,000 after purchasing an additional 47 shares in the last quarter. Graypoint LLC boosted its stake in Insulet by 5.3% in the 4th quarter. Graypoint LLC now owns 930 shares of the medical instruments supplier’s stock worth $243,000 after purchasing an additional 47 shares during the period. Wedmont Private Capital grew its holdings in Insulet by 3.5% during the 3rd quarter. Wedmont Private Capital now owns 1,433 shares of the medical instruments supplier’s stock valued at $326,000 after buying an additional 48 shares in the last quarter. Finally, OVERSEA CHINESE BANKING Corp Ltd increased its position in shares of Insulet by 4.7% during the third quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 1,076 shares of the medical instruments supplier’s stock valued at $250,000 after buying an additional 48 shares during the period.

Insider Transactions at Insulet

In related news, CAO Lauren Budden sold 915 shares of Insulet stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $275.62, for a total value of $252,192.30. Following the transaction, the chief accounting officer now owns 5,733 shares in the company, valued at $1,580,129.46. This trade represents a 13.76 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.47% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on PODD shares. Citigroup raised their price objective on shares of Insulet from $283.00 to $310.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Raymond James raised their price target on shares of Insulet from $213.00 to $260.00 and gave the company an “outperform” rating in a report on Monday, October 14th. TD Cowen upped their price target on shares of Insulet from $264.00 to $324.00 and gave the stock a “buy” rating in a report on Friday, January 3rd. Wells Fargo & Company lifted their price objective on Insulet from $290.00 to $305.00 and gave the company an “overweight” rating in a research note on Wednesday, December 11th. Finally, JPMorgan Chase & Co. upped their target price on Insulet from $280.00 to $330.00 and gave the stock an “overweight” rating in a research note on Thursday, December 12th. Three analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $272.81.

Insulet Stock Up 3.2 %

Shares of PODD opened at $272.86 on Friday. Insulet Co. has a 1 year low of $160.19 and a 1 year high of $279.77. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The stock has a 50 day simple moving average of $265.59 and a two-hundred day simple moving average of $231.62. The firm has a market cap of $19.14 billion, a P/E ratio of 46.72, a P/E/G ratio of 3.41 and a beta of 1.22.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.